Aldeyra Q3: Cash Down to $41M, Loss Narrows, FDA Appeal Pending
ALDX sits 17% above its 52-week low of $0.527.
Summary
Aldeyra ended Q3 2026 with $41.0M in cash, enough to fund operations into 2029, while it appeals the FDA's reproxalap rejection and carries a narrowed $12.7M nine-month loss.
Key Events · Earnings and Guidance · ALDX
-
Cash Falls to $41.0M
Cash and cash equivalents were $40,974,979 at September 30, 2026, down from $70,041,254 at December 31, 2025, after the $15.0M Hercules loan repayment.
-
Loss Narrows on R&D Cuts
Nine-month net loss was $12.7M versus $27.4M a year earlier; R&D fell 63.8% to $7.7M as focus shifted from clinical to regulatory work.
-
Runway Into 2029
Management states cash is sufficient to fund projected operating expenses into 2029, including the FDRR process.
-
FDA Appeal Filed
An FDRR appealing the 2026 Complete Response Letter for reproxalap was submitted October 26, 2026, with an OND meeting expected in Q4 2026.
Analysis · ALDX · Life Sciences
The quarter's headline is the shrinking cash pile: $41.0M at September 30 versus $70.0M at year-end, after repaying the $15.0M Hercules loan in April. Management says that cash funds operations into 2029, which buys time while the company appeals the FDA's March 2026 Complete Response Letter for reproxalap through a Formal Dispute Resolution Request filed October 26, 2026. The loss narrowed sharply ($12.7M for nine months vs $27.4M) mostly because R&D spending fell 63.8% as the company shifted from clinical work to regulatory activity. The AbbVie option remains unexercised as of November 5, 2026, so the $100M upfront and up to $300M in milestones are still contingent on an FDA approval that has not happened. A securities class action over prior reproxalap disclosures was amended October 9, 2026, adding legal overhang.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALDX was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.2M. The 52-week trading range was $0.53 to $5.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.